ZARR

News and price dashboard

Swept 16:22
Sources
27, all reachable
Items
51279
Flagged
6165
Last swept
16:22

Sources

All 27 enabled. Mute or unmute any of them.

Show stories from muted sources

STOCKS

120

OPTIONS

25

COMING UP

US majors and your names' earnings, next 7 days

Full calendar

Everything else — unscored, browse only, never pushed

Brief

Bank of America's Q3 miss and $1.2bn AML charge

The biggest substance in the feed is Bank of America. Shares fell 4.2% pre-open after Q3 2026 results missed on both lines and the bank absorbed a $1.2 billion regulatory charge for anti-money-laundering and sanctions compliance failures. Adjusted EPS was $1.08 against roughly $1.10 expected, GAAP net income fell 17% year over year to $6.9 billion ($0.91 a share, with the settlement worth $0.17 of that), and revenue came in near $30.0–30.12 billion versus about $30.7 billion expected. Trading was the weak spot: bond trading down 17% to $2.55 billion, equities down 10% to $2.51 billion, investment banking fees down 11% to $1.8 billion, broadly in line with what Brian Moynihan had flagged in September. The $1.21 billion penalty, announced by Treasury and FinCEN and described as the largest in OCC history, covers failures to flag over $5 billion in suspicious transactions, and had already knocked the stock more than 2% after hours on Tuesday. Bright spots were net interest income up 8% to $16.4 billion and a tenth straight quarter of sequential loan growth. TD Cowen had recently resumed coverage at Hold with a $60 target. The stock was quoted at $51.68 against a prior close of $53.96, and a separate newswire headline in the feed has it down 5.5% premarket.

State Street sells off despite an EPS beat

State Street fell in pre-open trade after reporting Q3 EPS of $3.69, which technically cleared the roughly $3.60–3.68 consensus. Two versions of the same Investing.com piece are in the feed quoting different pre-market declines, 6.1% and 7.52%, and the article is explicit that it does not know what in the report caused the reaction, speculating about expenses, net interest income or outlook commentary without resolving it. Context it does give: the stock had already shed about 7% over the prior month on fee-income and cost-inflation concerns, and Truist had kept a Hold while trimming its target. A separate headline-only post quotes the CEO on entering the final quarter "with strong momentum" alongside a revenue miss and the stock down 8.7% premarket.

The rest of the bank reporting day

State Street, Morgan Stanley and BlackRock all reported before the same open. BlackRock beat clearly, with Q3 EPS of $15.93 against $14.30 expected and revenue of $7.75 billion versus $7.44 billion; the stock had closed at $1,066.12 and is down 11.35% over twelve months. Headline-only items add that BlackRock took $205 billion of net inflows in the quarter and $869 billion over the past year, with 12% technology ACV growth, and show the stock up more than 4% premarket. Morgan Stanley, headline-only, posted net revenues of $20.3 billion, EPS of $3.03 and ROTCE of 22.6%, beating on both lines with equities trading at $5.80 billion against $4.90 billion expected, yet the feed carries a piece asking why the stock was slipping and quotes it down 0.6% premarket. Progressive is listed as a double miss, down 3.5% premarket, and Fastenal down 5.0%. Taken together the day's prints are mixed rather than directional, and the market reaction has been unkind even to the beats.

Lonza's capital markets day

Lonza rose 2.5% to CHF 580.6 after setting new medium-term targets at its Vacaville capital markets day: 10–13% average organic constant-currency sales growth and a core EBITDA margin in the "high thirties" over five years, against consensus sitting around 35.7%. ZKB's Daniel Jelovcan said the margin target came in well above expectations, with analysts now modelling 37–39% by 2031. Q3 met expectations across platforms and the full-year guidance of 11–12% growth and a 33–34% margin was kept. Lonza also committed to a stable or growing dividend and confirmed a CHF 500 million buyback for Q4 2026 after the Capsules & Health Ingredients disposal, and said Vacaville could reach peak sales of up to CHF 2 billion in the early 2030s.

Brinker upgrade plus credit outlook lift

Brinker International rose 1.9% pre-open on two things arriving at once. Jefferies upgraded it to Buy from Hold with a target of $255 from $230, arguing the turnaround is complete and drawing a comparison to Darden's multi-year transformation. The evening before, S&P Global Ratings moved its outlook to positive from stable while affirming the BB+ rating, citing leverage falling to 1.6x in fiscal 2026 from 1.8x, EBITDA margin up 60 basis points to 18.4%, and a new policy of keeping leverage under 2.0x. Previous close was $202.35.

Smaller corporate news with actual content

Enovix jumped 10.4% premarket on a purchase order for 100,000 battery units from an unnamed multinational drone systems provider, with deliveries scheduled for the first half of 2027 from its TAA-compliant, military-qualified plant in South Korea; the order converts one opportunity from the roughly $216 million drone, defence and industrial pipeline the company disclosed on 12 October. Evolution Metals reaffirmed fiscal 2027 revenue guidance of $400–460 million and fiscal 2026 of $10–11 million, said seven of its eight NdFeB magnet grades have cleared customer certification, and reported the first 13 of 57 containers of ULVAC equipment arriving in Pohang toward capacity above 10,000 metric tons. Sunrun and Tesla discharged a record 745 MW from residential batteries into California's grid on 6 October during a heat wave, beating the 669 MW set the day before, with day-ahead prices above $200/MWh triggering the dispatches. Gevo signed a three-year deal with CEEZER for a five-figure tonnage of carbon removal credits from its North Dakota CCS project through 2029. H.C. Wainwright kept Buy and an $8.00 target on Prelude Therapeutics, which trades at $3.56, following a trial collaboration with Eli Lilly supplying abemaciclib and imlunestrant for a Phase 1 of its KAT6A degrader PRT13722 starting in Q4 2026. Niki BioSolutions' DiamiR unit will run plasma-based APOE genotyping on the Bio-Hermes-002 Alzheimer's cohort.

Middle East shipping and oil

Several headline-only posts point the same way on energy risk. One reports a container ship sinking near the Strait of Hormuz after being hit by a projectile, with a dry bulk ship reported sinking in a separate incident nearby. Another says Iran is changing tactics to intensify attacks on shipping in the strait to keep oil prices elevated ahead of the 3 November US elections. There are also reports of a Yemeni missile attack on Saudi Arabia, a drone "collision" with an Iranian fishing vessel, and new US drone and communications capabilities deployed in the region via Task Force 99. Separately, the IEA is reported to have cut its 2026 oil demand outlook citing a diesel crisis and the Mideast war. The quote panels embedded in the full-text articles show WTI around $95.4 and Brent around $105.8.

Everything else is noise

A large share of the remaining items are Form 4 insider filings with no detail attached, several of them Progressive officers and directors for 9 October, plus a long run of TradingView chart posts on gold, bitcoin, silver and indices that are individual traders' setups, not news. The two TradingView pieces read in full are from the same author and simply lay out price levels he's watching on gold around $4,146 and bitcoin above $80,000. There is also a steady drip of Cantor Fitzgerald target cuts across regional banks (BankUnited to $52, Citizens Financial to $78, East West Bancorp, First Financial Bankshares to $34, Cullen/Frost to $167), which is the one connective thread in the headline-only analyst flow and sits alongside the soft bank earnings tone. Nothing in that group carries detail beyond the headline.

20 read in full, 200 items in the section

Feed

156 stories · 156 newCross-publisher stories only
  1. Pinned
  2. 156 new
  3. The 5% Price Tag on Everything
    Money & Markets [PROMO]
  4. AbbVie stock hits all-time high at 283.44 USD
    Investing.com - UK 14 itemsalso Investing.com - news, Investing.com - UK
  5. Fastenal Q3 2026 slides: earnings growth outpaces 15.5% sales gain
    Investing.com - news 2 itemsalso Investing.com - UK
  6. CBL Properties declares $0.625 quarterly dividend
    Investing.com - news 2 itemsalso Investing.com - UK
  7. Fcncp stock hits 52-week low at 17.52 USD
    Investing.com - UK 18 itemsalso Investing.com - UK, Investing.com - news
  8. Kenya reports second Ebola case linked to Congo outbreak
    Investing.com - UK 2 itemsalso Investing.com - news
  9. change the trend
    TradingView [COMMENT]
  10. check the trend
    TradingView [COMMENT]